Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             382 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Abnormalities of hypothalamus-pituitary-adrenal axis function and natural killer cell activity in Alzheimer's disease Griot, G.
 1996
 6 S4 p. S4-91-S4-94
NaN p.
 artikel
2 Abnormal regional cerebral blood flow in opioid dependent patients Fischer, G.
 1996
 6 S4 p. S4-129-
1 p.
 artikel
3 Acamprosate and relapse prevention: Results from a pooled analysis of 11 randomised placebo-controlled trials in 3338 alcohol-dependent patients Sass, H.
 1996
 6 S4 p. S4-7-
1 p.
 artikel
4 A comparative in vitro and in vivo characterization of the novel dopamine D3 receptor antagonists, (+)S 14297, nafadotride, GR 103,691 and U 99,194 Audinot, V.
 1996
 6 S4 p. S4-122-S4-123
NaN p.
 artikel
5 A comparison of extrapyramidal syndromes between olanzapine and placebo in shcizophrenia Street, J.S.
 1996
 6 S4 p. S4-122-
1 p.
 artikel
6 A comparison of the full 5-HT1A agonist flesinoxan with other 5-HT1A agonists: Effects on behaviour and a quantification of (partial) agonism on cells Mos, J.
 1996
 6 S4 p. S4-140-
1 p.
 artikel
7 A comparison of the incidence of long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol Street, J.S.
 1996
 6 S4 p. S4-122-
1 p.
 artikel
8 A comparison of zolpidem and temazepam in psychophysiological insomniacs Kerkhof, G.A.
 1996
 6 S4 p. S4-155-S4-156
NaN p.
 artikel
9 Acute phase efficacy and safety of olanzapine: A review Kuntz, A.
 1996
 6 S4 p. S4-115-
1 p.
 artikel
10 Acute tyrosine depletion reduces catecholamine synthesis in the rat brain McTavish, S.F.B.
 1996
 6 S4 p. S4-163-
1 p.
 artikel
11 Adenosine A2A agonists: A potential, new type of atypical antipsychotics Ögren, S.O.
 1996
 6 S4 p. S4-21-S4-22
NaN p.
 artikel
12 Adjunctive therapy in severe depression Dinan, T.G.
 1996
 6 S4 p. S4-4-
1 p.
 artikel
13 A double action antidepressant: Venlafaxine Puech, A.J.
 1996
 6 S4 p. S4-45-S4-46
NaN p.
 artikel
14 A drug discrimination rocedure in the pigeon confirms the in vitro agonistic action of flesinoxan on the 5-HT1A receptor Herremans, A.H.J.
 1996
 6 S4 p. S4-85-
1 p.
 artikel
15 A meta-analysis of magnetic resonance imaging studies in schizophrenia Vita, A.
 1996
 6 S4 p. S4-45-
1 p.
 artikel
16 Amiridin efficacy in Alzheimer's disease and multi-infarct dementia: The resemblance and the distinction Bukatina, E.E.
 1996
 6 S4 p. S4-101-
1 p.
 artikel
17 Amisulpride in the treatment of deficit schizophrenia Rein, W.
 1996
 6 S4 p. S4-106-
1 p.
 artikel
18 Amisulpride in the treatment of productive schizophrenia Rein, W.
 1996
 6 S4 p. S4-105-S4-106
NaN p.
 artikel
19 An aminopyrimidine with potent affinity for both dopamine and serotonin reoeptors Wustrow, D.
 1996
 6 S4 p. S4-107-
1 p.
 artikel
20 A new method to quantify effects of benzodiazepines on normal daily activities: Ambulatory accelerometry in psychopharmacological research Tulen, J.H.M.
 1996
 6 S4 p. S4-142-
1 p.
 artikel
21 Animal models of panic disorder — emphasis on face and predictive validity Jenck, F.
 1996
 6 S4 p. S4-47-
1 p.
 artikel
22 Antibodies against serotonin and gangliosides in fibromyalgia and major depression Samborski, W.
 1996
 6 S4 p. S4-74-S4-75
NaN p.
 artikel
23 Antibodies to human heat shock protein in patients with schizophrenia and major depression Sirota, P.
 1996
 6 S4 p. S4-114-
1 p.
 artikel
24 Antibodies to serotonin and cathecholamines as neuroimmunumodulators in experimental opiate addiction Basharova, L.A.
 1996
 6 S4 p. S4-130-
1 p.
 artikel
25 Anticipation and dynamic mutations in psychiatry Souery, D.
 1996
 6 S4 p. S4-58-S4-59
NaN p.
 artikel
26 Antidepressant effects of tianeptine, of its two enantiomers and its predominant metabolite in the learned helplessness test in rats Lacroix, P.
 1996
 6 S4 p. S4-70-
1 p.
 artikel
27 Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist in the forced swimming test in rats Dereń-Wesołek, A.
 1996
 6 S4 p. S4-74-
1 p.
 artikel
28 Antidepressant profile of the 5-HT1A agonist Flesinoxan in various forced-swim test paradigms van der Heyden, J.A.M.
 1996
 6 S4 p. S4-85-S4-86
NaN p.
 artikel
29 Antidepressants combined with acupuncture in therapy of endogenous depressions Gorobets, L.N.
 1996
 6 S4 p. S4-89-S4-90
NaN p.
 artikel
30 Antidepressant therapy and dopamine D2 receptors measured with SPECT D’haenen, H.
 1996
 6 S4 p. S4-72-
1 p.
 artikel
31 Antisense “knockout” of brain dopamine receptors: Potential antipsychotics? Creese, Ian
 1996
 6 S4 p. S4-27-
1 p.
 artikel
32 Anxiolytic effects found in the fear-potentiated startle response paradigm are not due to a non-specific disruption of startle behavior Joordens, R.J.E.
 1996
 6 S4 p. S4-145-S4-146
NaN p.
 artikel
33 A parametric evaluation of the effects of cyanamide on ethanol intake and preference in rats Maurel Remy, S.
 1996
 6 S4 p. S4-131-S4-132
NaN p.
 artikel
34 A polymorphic region in the human tyrosine hydroxylase gene is associated with disturbances of the catecholaminergic system in schizophrenia Thibaut, F.
 1996
 6 S4 p. S4-113-
1 p.
 artikel
35 A reappraisal of the role of serotonin versus GABAergic interaction in emotional control Nazar, M.
 1996
 6 S4 p. S4-140-S4-141
NaN p.
 artikel
36 A review of the efficacy of “Seroquel” (quetiapine) in the treatment of the positive and negative symptoms of schizophrenia Hellewell, J.S.E.
 1996
 6 S4 p. S4-14-S4-15
NaN p.
 artikel
37 Assessment of the pharmacodynamic interaction between phenytoin and sodium valproate by ictal behaviour analysis Della Paschoa, O.E.
 1996
 6 S4 p. S4-161-
1 p.
 artikel
38 Association study of bipolar disorder and a serotonin receptor polymorphism Mahieu, B.
 1996
 6 S4 p. S4-84-
1 p.
 artikel
39 Attentional abnormalities in an animal model for developmental disorders of the entorhinal cortex Talamini, L.M.
 1996
 6 S4 p. S4-116-S4-117
NaN p.
 artikel
40 Attentional capacity in normal control and ADHD children, a probe ERP study Jonkman, L.M.
 1996
 6 S4 p. S4-156-
1 p.
 artikel
41 Author index 1996
 6 S4 p. S4-169-S4-174
NaN p.
 artikel
42 Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects van Berckel, B.N.M.
 1996
 6 S4 p. S4-102-
1 p.
 artikel
43 Benzodiazepine binding in T-lymphocytes from parkinsonian patients Bongioanni, P.
 1996
 6 S4 p. S4-96-S4-97
NaN p.
 artikel
44 BIMT 17: A putative fast acting antidepressant Borsini, F.
 1996
 6 S4 p. S4-23-S4-24
NaN p.
 artikel
45 Biochemical and neuroendocrinergic indicators of aggressive behavior: A controlled study Çetin, M.
 1996
 6 S4 p. S4-158-
1 p.
 artikel
46 Bizarre delusions and age of onset in schizophrenic patients Dikeos, D.G.
 1996
 6 S4 p. S4-118-
1 p.
 artikel
47 Blunted reaction to the citalopram challenge test in patients with major depression Kapitany, T.
 1996
 6 S4 p. S4-80-
1 p.
 artikel
48 Calcium channel blockers prevent memory impairment induced by the beta-blockers acebutolol and metoprolol Lazarova-Bakarova, M.
 1996
 6 S4 p. S4-96-
1 p.
 artikel
49 Case-control and neuro-imaging study in persons with schizophrenia after prenatal exposure to the Dutch Famine in 1945 Kalkman, J.S.
 1996
 6 S4 p. S4-102-
1 p.
 artikel
50 Changes in composition of phospholipids and fatty acids in rat brain during aging Řípovà, D.
 1996
 6 S4 p. S4-95-S4-96
NaN p.
 artikel
51 Characteristics of patients with a prescription of benzodiazepine Barnas, C.
 1996
 6 S4 p. S4-148-
1 p.
 artikel
52 Characterization and inhibition of human cytochrome P-450 enzymes involved in the in vitro metabolism of mirtazapine Verhoeven, C.H.J.
 1996
 6 S4 p. S4-63-
1 p.
 artikel
53 Characterization of [3H]GR 125,743 as a radioligand at 5-HT1Dreceptors in guinea pig brain: A comparison with [3H]5CT Audinot, V.
 1996
 6 S4 p. S4-151-
1 p.
 artikel
54 Cholecystokinin peptides in cerebrospinal fluid: Findings in healthy male volunteers Gunnarsson, T.
 1996
 6 S4 p. S4-160-
1 p.
 artikel
55 Chronic immunological process in schizophrenia Sluzewska, A.
 1996
 6 S4 p. S4-108-
1 p.
 artikel
56 Chronic mild stress causes a decrease in the preference for low ethanol concentrations in male Wistar rats Smith, J.W.
 1996
 6 S4 p. S4-131-
1 p.
 artikel
57 Clinical and experimental sleep study of acute and long-term effects of mood stabilizes Mosolov, S.N.
 1996
 6 S4 p. S4-89-
1 p.
 artikel
58 Clinical and neuroendocrine response to fluvoxamine treatment in impulsive borderline personality disorder Rinne, Th.
 1996
 6 S4 p. S4-73-
1 p.
 artikel
59 Clinical differences in response to mianserin and fluvoxamine in depressive patients Lavergne, F.
 1996
 6 S4 p. S4-82-
1 p.
 artikel
60 Clinical effects of buspirone in social phobia, a double-blind placebo controlled study van Vliet, I.M.
 1996
 6 S4 p. S4-150-
1 p.
 artikel
61 Clinical profile of mirtazapine van Moffaert, M.
 1996
 6 S4 p. S4-63-S4-64
NaN p.
 artikel
62 Clinical relevence of antibodies against serotonin and gangliosides, and acute phase proteins in major depression Sluzewska, A.
 1996
 6 S4 p. S4-75-
1 p.
 artikel
63 Clinico-pharmacokinetic prognosis of prophylactic efficacy of carbamazepine, oxcarbazepine and sodium valproate in affective and schizoaffective disorders Kouzavkova, M.
 1996
 6 S4 p. S4-90-
1 p.
 artikel
64 Cloning and characterization of a rat μ-opioid receptor isoform (rMOR1B) Zimprich, A.
 1996
 6 S4 p. S4-136-
1 p.
 artikel
65 Clozapine in refractory schizophrenic disorders: A longitudinal study of efficiency, tolerability and clinical improvement during a period up to four years Maître, L.
 1996
 6 S4 p. S4-107-
1 p.
 artikel
66 Clozapine treatment and psychosocial rehabilitation on schizophrenia longitudinal study on positive and negative symptoms in neuroleptic non responder patients Marchetti, S.
 1996
 6 S4 p. S4-117-
1 p.
 artikel
67 Clozapine treatment of severe tardive dystonia Cavallaro, R.
 1996
 6 S4 p. S4-133-S4-134
NaN p.
 artikel
68 CNS depressant effects of olfactory stimulation in rats Komori, T.
 1996
 6 S4 p. S4-159-
1 p.
 artikel
69 Codependecy and personality traits in alcoholics and their partners Janiri, L.
 1996
 6 S4 p. S4-136-S4-137
NaN p.
 artikel
70 Cognitive and behaviourial therapies for social phobia Freeman, C.P.L.
 1996
 6 S4 p. S4-37-S4-38
NaN p.
 artikel
71 Combination of two SSRI's in long-term treatment of patients with OCD-four case reports Pálová, Eva
 1996
 6 S4 p. S4-148-
1 p.
 artikel
72 Combination treatments with rapid onset of action in major depression Blier, P.
 1996
 6 S4 p. S4-23-
1 p.
 artikel
73 Combined pharmakotherapy (Tramadon and mianserin) in chronic pain syndrome Marko, Munjiza G.
 1996
 6 S4 p. S4-78-S4-79
NaN p.
 artikel
74 Combined use of carbamazepine and valproic acid in negative symptom schizophrenia Min-Soo, Lee
 1996
 6 S4 p. S4-105-
1 p.
 artikel
75 Comorbidity between obsessive compulsive disorder and unipolar and bipolar disorders Pfanner, C.
 1996
 6 S4 p. S4-149-
1 p.
 artikel
76 Comorbid mood disturbance in schizophrenia Tollefson, G.D.
 1996
 6 S4 p. S4-105-
1 p.
 artikel
77 Comparative efficacy of moclobemide and imipramine on anxiety features in major depression- a meta-analysis of double blind comparative studies against placebo Delini-Stula, Alexandra
 1996
 6 S4 p. S4-80-S4-81
NaN p.
 artikel
78 Comparison of amisulpride and seelctive serotonine reuptake inhibitors efficacy on cognitive and anxious symptoms in dysthymic disorder Scotta, M.
 1996
 6 S4 p. S4-76-
1 p.
 artikel
79 Comparison of brain activity patterns during finger opposition with and without tactile stimulation using a BOLD-fMRI method Jansma, J.M.
 1996
 6 S4 p. S4-167-
1 p.
 artikel
80 Controlled trials versus naturalistic studies Brown, R.E.
 1996
 6 S4 p. S4-53-S4-54
NaN p.
 artikel
81 Correlates and course of irritability and disinhibition during alprazolam treatment of panic disorder Starcevic, Vladan
 1996
 6 S4 p. S4-144-
1 p.
 artikel
82 Corticotropin-releasing hormone (CRH) neurons in the hypothalamic paraventricular nucleus of depressed and non-depressed parkinsonian patients with and without dementia Hoogendijk, W.J.G.
 1996
 6 S4 p. S4-94-
1 p.
 artikel
83 Cortisol and temperature responses to flesinoxan in alcoholism Pitchot, W.
 1996
 6 S4 p. S4-129-S4-130
NaN p.
 artikel
84 Cost-effectiveness of treatments for schizophrenia Kerwin, R.W.
 1996
 6 S4 p. S4-54-
1 p.
 artikel
85 Course of illness in schizophrenia in relation to duration of initially untreated psychosis Waddington, J.L.
 1996
 6 S4 p. S4-31-S4-32
NaN p.
 artikel
86 D2 dopamine receptor occupancy (IBZM-SPECT) and extrapyramidal symptoms under treatment with risperidone Mager, T.
 1996
 6 S4 p. S4-102-S4-103
NaN p.
 artikel
87 Depression and false depression in alcoholism: An application of brain mapping Garrido, A.
 1996
 6 S4 p. S4-135-
1 p.
 artikel
88 Depressive symptoms in stable chronic schizophrenia: Prevalence and relationship to psychopathology and medication status Mulholland, C.
 1996
 6 S4 p. S4-118-
1 p.
 artikel
89 Detection on 5HT7 receptors using [3H]risperidone: A brain regional distribution Gommeren, W.
 1996
 6 S4 p. S4-120-
1 p.
 artikel
90 Developmental processes and immunology in schizophrenia Müller, Norbert
 1996
 6 S4 p. S4-44-
1 p.
 artikel
91 Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in isolated tissues Capasso, A.
 1996
 6 S4 p. S4-130-
1 p.
 artikel
92 Different traits of personality and Cloninger's types of alcoholism Hadjichristos, A.
 1996
 6 S4 p. S4-137-
1 p.
 artikel
93 Discrimination between the 5-HT1 receptor agonists flesinoxan and eltoprazine Gommans, J.
 1996
 6 S4 p. S4-145-
1 p.
 artikel
94 Disruption of circadian rhythms in possible animal models for depression Turek, F.W.
 1996
 6 S4 p. S4-35-S4-36
NaN p.
 artikel
95 Disturbed stress response in Multiple Complex Developmental Disorder and schizophrenia: Salivary cortisol response to a psychological stressor as a measure Cittadini, L.M.C.
 1996
 6 S4 p. S4-121-
1 p.
 artikel
96 Does severe depression have a different pharmacology? Aschauer, H.N.
 1996
 6 S4 p. S4-3-S4-4
NaN p.
 artikel
97 Does Venlafaxin have early onset? Möller, H.-J.
 1996
 6 S4 p. S4-24-
1 p.
 artikel
98 Dopamine-GABA interactions in relation to schizophrenia Benes, Francine M.
 1996
 6 S4 p. S4-43-S4-44
NaN p.
 artikel
99 Dopaminergic and nicotinic interactions in the human striatum in dementia with lewy bodies, chronic schizophrenia and Parkinson's disease Piggott, M.A.
 1996
 6 S4 p. S4-104-
1 p.
 artikel
100 Dopaminergic properties of the 5-HT1A receptor antagonists WAY-100,635 and (S)-UH-301 Ahlenius, Sven
 1996
 6 S4 p. S4-151-S4-152
NaN p.
 artikel
101 Early intervention and the course of illness Schooler, N.R.
 1996
 6 S4 p. S4-33-
1 p.
 artikel
102 EEG abnormalities in anxiety disorders Brezezinski, R.
 1996
 6 S4 p. S4-150-S4-151
NaN p.
 artikel
103 EEG and event related potentials as indicators of central neurophysiological effects of acamprosate Gallinat, J.
 1996
 6 S4 p. S4-134-
1 p.
 artikel
104 Effectiveness of pemoline among hyperkinetic children who fail to respond to methylphenidate Winsberg, B.G.
 1996
 6 S4 p. S4-166-
1 p.
 artikel
105 Effect of flesinoxan on the electrocorticogram of the rat Nievelstein, H.
 1996
 6 S4 p. S4-147-
1 p.
 artikel
106 Effect of long-term maintenance psychotropic therapy on occupational adaptation of schizophrenic patients Kiryanova, E.M.
 1996
 6 S4 p. S4-128-
1 p.
 artikel
107 Effect of plasmapheresis in the treatment of drug-resistant schizophrenic patients with biochemical and immunological control Malin, D.I.
 1996
 6 S4 p. S4-128-S4-129
NaN p.
 artikel
108 Effects of μ and κ opioid agonists on the cholecystokinin-induced activation of opioid system in isolated guinea-pig ileum Romanelli, L.
 1996
 6 S4 p. S4-134-
1 p.
 artikel
109 Effects of clozapine on medial prefrontal cortical cells: A presynaptical hypothesis Gobbi, G.
 1996
 6 S4 p. S4-117-
1 p.
 artikel
110 Effects of differential early social experience on biological and behavioral development in rhesus monkeys Suomi, Stephen J.
 1996
 6 S4 p. S4-52-
1 p.
 artikel
111 Effects of nitric oxide synthase inhibition on ethanol withdrawal syndrome in rats Uzbay, İ.T.
 1996
 6 S4 p. S4-130-S4-131
NaN p.
 artikel
112 Effects of repeated administration of desipramine and fluoxetine on vasopressin-induced grooming in rats Lightowler, S.
 1996
 6 S4 p. S4-157-
1 p.
 artikel
113 Effects of selective serotonin reuptake inhibitors given repeatedly on 5-HT receptor subpopulations in the rat brain Maj, J.
 1996
 6 S4 p. S4-75-
1 p.
 artikel
114 Effects of sex and aging on 3H-paroxetine binding to human platelets Marazziti, D.
 1996
 6 S4 p. S4-162-
1 p.
 artikel
115 Effects of vasopressin metabolites on social recognition in the rat Reijmers, L.G.J.E.
 1996
 6 S4 p. S4-165-S4-166
NaN p.
 artikel
116 Efficacy and safety of fluoxetine in major depression Çetin, M.
 1996
 6 S4 p. S4-71-S4-72
NaN p.
 artikel
117 Efficacy measurement with the new panic and agoraphobia scale by using a new nonparametric test for repeated measures Bandelow, B.
 1996
 6 S4 p. S4-152-
1 p.
 artikel
118 Efficacy of different serotonergic drugs in obsessive-compulsive disorder Pfaner, C.
 1996
 6 S4 p. S4-148-S4-149
NaN p.
 artikel
119 Efficacy of mirtazapine in moderate and severe depression Pinder, R.M.
 1996
 6 S4 p. S4-62-
1 p.
 artikel
120 Efficacy of mirtazapine vs clomipramine in severely depressed, hospitalized patients Peyron, E.
 1996
 6 S4 p. S4-61-
1 p.
 artikel
121 Efficacy of the full 5-HT1A receptor agonist flesinoxan compared with other 5-HT1A agonists in animal models for anxiety Mos, J.
 1996
 6 S4 p. S4-147-S4-148
NaN p.
 artikel
122 Endorphins and experimental drug addiction Gerrits, M.A.F.M.
 1996
 6 S4 p. S4-5-S4-6
NaN p.
 artikel
123 Enzymes of the antioxidant system in type II schizophrenia Paunovic, V.R.
 1996
 6 S4 p. S4-127-
1 p.
 artikel
124 Enzymes of the antioxidant system in Type I schizophrenia Miljevic, C.D.
 1996
 6 S4 p. S4-127-S4-128
NaN p.
 artikel
125 Epidemiological study on extrapyramidal side effects with neuroleptics Berardi, D.
 1996
 6 S4 p. S4-111-
1 p.
 artikel
126 Epileptic agents in bipolar depression Ferrier, I.N.
 1996
 6 S4 p. S4-30-
1 p.
 artikel
127 ERP waves of ADHD- and normal control children in a continuous performance test Overtoom, C.C.E.
 1996
 6 S4 p. S4-160-
1 p.
 artikel
128 Evaluating the benefits of antidepressant therapy — Modelling the impact on quality of life Kind, P.
 1996
 6 S4 p. S4-52-S4-53
NaN p.
 artikel
129 Event-related potentials and selective auditory and visual attention in autism Hoeksma, M.R.
 1996
 6 S4 p. S4-103-
1 p.
 artikel
130 Event related potentials as indicators of central serotonergic activity Hegerl, U.
 1996
 6 S4 p. S4-9-S4-10
NaN p.
 artikel
131 Expression of IL-6 receptor mRNA in the hypothalamus of restrained rat Komori, T.
 1996
 6 S4 p. S4-159-
1 p.
 artikel
132 Extrapyramidal symptoma and tolerability of olanzapine versus haloperidol in acute treatment Dellva, M.A.
 1996
 6 S4 p. S4-106-
1 p.
 artikel
133 Eye movements of autistic children van der Geest, J.N.
 1996
 6 S4 p. S4-156-
1 p.
 artikel
134 Ferment status of lymphocytes in children born by parents with psychic diseases Ternovsky, L.N.
 1996
 6 S4 p. S4-164-S4-165
NaN p.
 artikel
135 Finding susceptibility genes for schizophrenia Owen, M.J.
 1996
 6 S4 p. S4-57-S4-58
NaN p.
 artikel
136 First episode schizophrenia: Treatment and outcome Amore, Mario
 1996
 6 S4 p. S4-119-S4-120
NaN p.
 artikel
137 Flesinoxan, a selective 5-HT1A receptor agonist, familiarizes with fluvoxamine and fluoxetine in a conditioned taste aversion procedure in mice Bouwknecht, J.A.
 1996
 6 S4 p. S4-76-
1 p.
 artikel
138 Flesinoxan in generalised anxiety disorder: A meta-analysis of two double-blind, placebo-controlled comparisons with alprazolam de Voogd, J.M.
 1996
 6 S4 p. S4-141-
1 p.
 artikel
139 Flesinoxan in the treatment of major depressive disorder: A fixed dose, placebo-controlled trial Prinsze, C.
 1996
 6 S4 p. S4-73-
1 p.
 artikel
140 Flesinoxan: microdialytic profiling of a 5-HT1A receptor agonist van der Heyden, J.A.M.
 1996
 6 S4 p. S4-68-S4-69
NaN p.
 artikel
141 Flesinoxan treatment of Generalized Anxiety Disorder: A fixed dose, placebo-controlled trial Noël, F.
 1996
 6 S4 p. S4-144-
1 p.
 artikel
142 Fluoxetine treatment of children and adolescents with obsessive-compulsive disorders: A open-label trial Baysal, Z.B.
 1996
 6 S4 p. S4-142-S4-143
NaN p.
 artikel
143 Fluoxetine treatment of comorbid premature ejaculation and panic disorder Kindler, S.
 1996
 6 S4 p. S4-146-S4-147
NaN p.
 artikel
144 Fluvoxamine augmentation in citalopram non-responders: A pharmacokinetic and clinical study Bondolfi, G.
 1996
 6 S4 p. S4-61-
1 p.
 artikel
145 Fluvoxamine effective in preventing recurrence of major depression Terra, J.L.
 1996
 6 S4 p. S4-65-
1 p.
 artikel
146 Fluvoxamine for children and adolescents with Obsessive Compulsive Disorder: A controlled multicenter trial Riddle, Mark A.
 1996
 6 S4 p. S4-144-S4-145
NaN p.
 artikel
147 Fluvoxamine in the treatment of obsessive-compulsive disorder: A double-blind comparison with clomipramine Mundo, E.
 1996
 6 S4 p. S4-139-S4-140
NaN p.
 artikel
148 Fluvoxamine versus desipramine in elderly patients with major depression: A double-blind comparison Tourigny-Rivard, M.
 1996
 6 S4 p. S4-74-
1 p.
 artikel
149 Forskolin effects on behavior in rats and in depressed and schizophrenic patients Bersudsky, Yuly
 1996
 6 S4 p. S4-90-
1 p.
 artikel
150 Free radical formation level in rabbit brain after experimental cranlocerebral trauma Demchuk, M.L.
 1996
 6 S4 p. S4-95-
1 p.
 artikel
151 Functional hypofrontality revealed by EEG coherence analysis of 16 antipsychotic-free schizophrenic patients performing cognitive activation paradigms Tauscher, J.
 1996
 6 S4 p. S4-107-S4-108
NaN p.
 artikel
152 Functional magnetic resonance imaging as a research tool: Quality assessment of PRESTO, a non-invasive three-dimensional imaging technique Ramsey, N.F.
 1996
 6 S4 p. S4-7-S4-8
NaN p.
 artikel
153 GABA-A receptor antagonists: Sex differences in pharmacokinetics and/or pharmacodynamics? Peričić, D.
 1996
 6 S4 p. S4-165-
1 p.
 artikel
154 Gene-environment interactions in complex psychiatric disorders Macciardi, F.
 1996
 6 S4 p. S4-59-
1 p.
 artikel
155 Genetics and function of GABAA-receptor subtypes Möhler, H.
 1996
 6 S4 p. S4-17-
1 p.
 artikel
156 Genetics of the Gilles de la Tourette syndrome and obsessive compulsive disorder Pauls, D.L.
 1996
 6 S4 p. S4-56-
1 p.
 artikel
157 H1-blockers induce deficit in active and passive avoidance performance in rats Georgieva, V.
 1996
 6 S4 p. S4-99-S4-100
NaN p.
 artikel
158 Histamine mediates long-term potentiation of excitability in rat hippocampus Selbach, O.
 1996
 6 S4 p. S4-162-S4-163
NaN p.
 artikel
159 5-HT6 and 5-HT7 receptors: New targets for neuropsychiatry Sleight, A.J.
 1996
 6 S4 p. S4-42-S4-43
NaN p.
 artikel
160 5-HT1A receptors, anxiety and stress: Behavioural, neuroendocrine and physiological interfaces Olivier, B.
 1996
 6 S4 p. S4-39-S4-40
NaN p.
 artikel
161 5-HT2 blocker ritancerin attenuates the behavioral expression of precipitated morphine abstinence Kudryashova, M.F.
 1996
 6 S4 p. S4-133-
1 p.
 artikel
162 5HT2 receptor subtypes: Central localisation, roles and possible therapeutic applications of agonists and antagonists Leysen, J.E.
 1996
 6 S4 p. S4-40-S4-41
NaN p.
 artikel
163 Hydroxylation polymorphism of debrisoquin hydroxylase (CYP2D6) in a population of psychotic patients in Norway and Denmark Dahl, A.A.
 1996
 6 S4 p. S4-108-
1 p.
 artikel
164 Hypoxia and hyperventilation as models for cognitive deficiencies Hogervorst, E.
 1996
 6 S4 p. S4-166-
1 p.
 artikel
165 Immediate early genes: Functions and responses to drugs Morgan, J.I.
 1996
 6 S4 p. S4-27-S4-28
NaN p.
 artikel
166 Immunosuppressive effect of neuroleptic drugs — is it integrated in their antipsychotic action? Leykin, I.
 1996
 6 S4 p. S4-113-
1 p.
 artikel
167 Increased D2/D3 dopamine receptor binding associated with pharmacotherapy response before and after treatment of major depression measured by single photon emission computed tomography (SPECT) Klimke, A.
 1996
 6 S4 p. S4-83-S4-84
NaN p.
 artikel
168 Increased oxidative stress in alcohol dependent patients as estimated by the in vivo acetylsalicylic acid assay (ASAA) Thome, J.
 1996
 6 S4 p. S4-138-
1 p.
 artikel
169 Inflammation and anti-inflammatory treatment strategies in Alzheimer's disease Winblad, B.
 1996
 6 S4 p. S4-34-
1 p.
 artikel
170 Interferon and interleukin-2 as modulators of alcohol behavioral reactions in C57B1/6 mice Fomina, V.G.
 1996
 6 S4 p. S4-132-
1 p.
 artikel
171 Intracerebroventricular (icv) administration of CCK-antisense oligodeoxynucleotides prevent anxiety-behavior in rats Cohen, H.
 1996
 6 S4 p. S4-153-S4-154
NaN p.
 artikel
172 Investigation of the selectivity of vesamicol analogues as markers for cholinergic neurons: Potential ligands for single photon emission computerized tomography (SPECT) in Alzherimer's disease Custers, F.G.J.
 1996
 6 S4 p. S4-100-
1 p.
 artikel
173 Involvement of corticotropin-releasing factor in addiction Heinrichs, S.C.
 1996
 6 S4 p. S4-5-
1 p.
 artikel
174 Is anhedonia a predictive factor for relapse in alcohol dependence? Marra, D.
 1996
 6 S4 p. S4-132-S4-133
NaN p.
 artikel
175 Is 5HT5D involved in obsessive compulsive disorder? Zohar, J.
 1996
 6 S4 p. S4-54-S4-55
NaN p.
 artikel
176 Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers Perault, M.C.
 1996
 6 S4 p. S4-103-S4-104
NaN p.
 artikel
177 Lack of typical SSRI-related adverse effects and sexual dysfunction with mirtazapine is related to specific blockade of 5-HT2 and 5-HT3 receptors Klint, T.
 1996
 6 S4 p. S4-61-S4-62
NaN p.
 artikel
178 Lamotrigine may limit pathological excitation by modulating calcium- and potassium currents Grunze, H.
 1996
 6 S4 p. S4-155-
1 p.
 artikel
179 Left hemispheric relative hypoperfusion in depressed patients with seasonal affective disorder responding to light therapy Praschak-Rieder, N.
 1996
 6 S4 p. S4-78-
1 p.
 artikel
180 Lithium withdrawal: Clinical consequences and changes in brain perfusion Goodwin, G.M.
 1996
 6 S4 p. S4-30-S4-31
NaN p.
 artikel
181 Localization of 5HT1Dα-and 5HT1Dβ-receptor mRNA by in situ hybridization in guinea pig brain and trigeminal ganglia Bonaventure, P.
 1996
 6 S4 p. S4-71-
1 p.
 artikel
182 Long-acting neuroleptics treatment of patients in residential rehabilitation programs Codazzi, L.
 1996
 6 S4 p. S4-98-
1 p.
 artikel
183 Long-term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience Tran, P.V.
 1996
 6 S4 p. S4-115-
1 p.
 artikel
184 Long-term effects of alprazolam on memory: A 3 1/2 year follow up of agoraphobic patients Kiliç, C.
 1996
 6 S4 p. S4-141-
1 p.
 artikel
185 Low serum cholesterol, serotonin and suicidal behavior Pitchot, W.
 1996
 6 S4 p. S4-67-
1 p.
 artikel
186 Magnetoencephalography (MEG) in the study of human brain functions Sams, M.
 1996
 6 S4 p. S4-9-
1 p.
 artikel
187 Maintenance of calcium-mediated metabolic control as a therapeutic principle in energy-compromised neurological disorders Heininger, K.
 1996
 6 S4 p. S4-98-
1 p.
 artikel
188 Maintenance of calcium-mediated metabolic control as a therapeutic principle in energy-compromised neurological disorders Heininger, K.
 1996
 6 S4 p. S4-98-S4-99
NaN p.
 artikel
189 Managed care and antidepressant pharmacotherapy: Economic considerations Robinson, L.M.
 1996
 6 S4 p. S4-54-
1 p.
 artikel
190 MAO and COMT: basic functions and therapeutic indications Richards, J.G.
 1996
 6 S4 p. S4-11-S4-12
NaN p.
 artikel
191 Mental retardation: Effectiveness of fluvoxamine in the treatment of depressive symptoms: Case reports Lenzi, A.
 1996
 6 S4 p. S4-64-
1 p.
 artikel
192 Messenger RNA for platelet 5HT transporter protein: Studies in rats with constitutionally altered serotonin homeostasis Jernej, B.
 1996
 6 S4 p. S4-77-
1 p.
 artikel
193 Metabotropic receptors and their involvement in cell death Pizzi, M.
 1996
 6 S4 p. S4-10-
1 p.
 artikel
194 Methodological issues in the outcomes assessment of a new, atypical antipsychotic Drummond, M.F.
 1996
 6 S4 p. S4-126-
1 p.
 artikel
195 Mianserin therapy of depressive patients with coexisting cardiovascular diseases Rajewska, Jolanta
 1996
 6 S4 p. S4-87-
1 p.
 artikel
196 Milnacipran, a double noradrenaline and 5-HT reuptake inhibiting antidepressant increases cerebral extracellular monoamine levels Moret, C.
 1996
 6 S4 p. S4-68-
1 p.
 artikel
197 Milnacipran, a double noradrenaline and serotonin reuptake inhibiting antidepressant Briley, M.
 1996
 6 S4 p. S4-46-
1 p.
 artikel
198 Mirtazapine: A dual action antidepressant which does not affect monoamine reuptake Pinder, R.M.
 1996
 6 S4 p. S4-46-
1 p.
 artikel
199 Mirtazapine versus tricyclic antidepressants: An overview of efficacy data Sitsen, J.M.A.
 1996
 6 S4 p. S4-62-
1 p.
 artikel
200 Mirtazapine versus tricyclic antidepressants in the treatment of severely depressed patients Zivkov, M.
 1996
 6 S4 p. S4-62-S4-63
NaN p.
 artikel
201 Modulation of drug reward by receptor ligands Zvartau, E.
 1996
 6 S4 p. S4-4-S4-5
NaN p.
 artikel
202 Molecular genetic studies in affective disorders Mendlewicz, J.
 1996
 6 S4 p. S4-26-S4-27
NaN p.
 artikel
203 Molecular pharmacology of NMDA receptors Williams, Keith
 1996
 6 S4 p. S4-50-
1 p.
 artikel
204 Monoaminergic systems in patients with Obsessive-Compulsive Disorder (OCD) before and after fluoxetine treatment Prolo, P.
 1996
 6 S4 p. S4-146-
1 p.
 artikel
205 Morphine counteracts the effects of juvenile isolation on later social behaviour van den Berg, C.L.
 1996
 6 S4 p. S4-163-S4-164
NaN p.
 artikel
206 Muscle enzymes and white blood count as risk factors for the neuroleptic malignant syndrome Hermesh, H.
 1996
 6 S4 p. S4-119-
1 p.
 artikel
207 Natural course of OCD Ravizza, L.
 1996
 6 S4 p. S4-15-
1 p.
 artikel
208 Negative symptoms and risperidone Peuskens, J.
 1996
 6 S4 p. S4-13-S4-14
NaN p.
 artikel
209 Negative symptoms and sertindole Kasper, S.
 1996
 6 S4 p. S4-13-
1 p.
 artikel
210 Neonatal pain and stress: Neural adaptations and long-term consequences Plotsky, P.M.
 1996
 6 S4 p. S4-51-S4-52
NaN p.
 artikel
211 Neuroactive steroids acting at GABAA receptors Gee, Kelvin W.
 1996
 6 S4 p. S4-17-S4-18
NaN p.
 artikel
212 Neuroendocrine challenge of serotonergic function with citalopram in healthy volunteers Kapitany, T.
 1996
 6 S4 p. S4-80-
1 p.
 artikel
213 Neuroendocrine effects of methylenedioxyethylamphetamine (MDE) in healthy volunteers: Preliminary results of an ongoing human experimental study Gouzoulis-Mayfrank, E.
 1996
 6 S4 p. S4-135-
1 p.
 artikel
214 Neuroendocrine studies in depression Holsboer, F.
 1996
 6 S4 p. S4-1-
1 p.
 artikel
215 Neuroimaging studies in children with Tourette syndrome and obsessive-comlpulsive disorder Buitelaar, J.K.
 1996
 6 S4 p. S4-56-S4-57
NaN p.
 artikel
216 Neuro-immuno-pharmacological effects of flobufen in model experiments with aging rats Benešová, O.
 1996
 6 S4 p. S4-99-
1 p.
 artikel
217 Neuroleptic malignant syndrome and psychosis in two siblings with gangliosidosis type II Manor, I.
 1996
 6 S4 p. S4-119-
1 p.
 artikel
218 Neuropathology of Alzheimer's disease with special reference to neurofibrillary tangles Braak, H.
 1996
 6 S4 p. S4-25-S4-26
NaN p.
 artikel
219 Neurosurgery for otherwise intractable OCD — An update Mindus, P.
 1996
 6 S4 p. S4-55-S4-56
NaN p.
 artikel
220 Neurotherapeutic potential of 5-HT3 receptor antagonists Palfreyman, M.G.
 1996
 6 S4 p. S4-41-S4-42
NaN p.
 artikel
221 Neurotransmitter receptors, genes and schizophrenia Reynolds, Gavin P.
 1996
 6 S4 p. S4-29-S4-30
NaN p.
 artikel
222 New molecular genetic studies in affective disorders Propping, Peter
 1996
 6 S4 p. S4-58-
1 p.
 artikel
223 New therapeutic strategy for migraine treatment: Desensitization with a dopamine agonist Lai, M.
 1996
 6 S4 p. S4-161-
1 p.
 artikel
224 Nimotop influence on free radical processes in the CSF of patients with subarachnoid haemorrhages Arefyeva, I.A.
 1996
 6 S4 p. S4-95-
1 p.
 artikel
225 No evidence of association between dopamine D3 receptor gene and bipolar disorder in a sardinian sample Severino, C.
 1996
 6 S4 p. S4-112-
1 p.
 artikel
226 Norharman in multiple drug-addicts and healthy controls Fekkes, D.
 1996
 6 S4 p. S4-129-
1 p.
 artikel
227 Novel neuroprotective strategies based on the enhancement of brain kynurenic acid levels Schwarcz, R.
 1996
 6 S4 p. S4-10-S4-11
NaN p.
 artikel
228 Novel substituted acyl-prolyl dipeptide, GVS-111, diminishes cognitive impairment on the model of ischemic stroke in rats Romanova, G.A.
 1996
 6 S4 p. S4-100-
1 p.
 artikel
229 Obsessive Compulsive Disorder with episodic course: Is it a mood disorder related subtype? Gemignani, A.
 1996
 6 S4 p. S4-149-
1 p.
 artikel
230 Olanzapine in the treatment of schizoaffective disorder Lu, Y.
 1996
 6 S4 p. S4-106-
1 p.
 artikel
231 Opiate antagonists in the treatment of alcohol dependence: Results of a UK study Chick, J.D.
 1996
 6 S4 p. S4-6-S4-7
NaN p.
 artikel
232 Optimized analysis of the D2 dopamine receptor occupancy by image fusion of corresponding I-123 IBZM-SPECT and MR-DATA Mager, T.
 1996
 6 S4 p. S4-102-
1 p.
 artikel
233 PANDAS: Pediatric autoimmune neuropsychiatric disorders associated with strep — is this a new species of childhood-onset obsessive-compulsive disorder and tourette's syndrome? Swedo, S.E.
 1996
 6 S4 p. S4-16-S4-17
NaN p.
 artikel
234 Panic disorder and agoraphobia: What is effective? Bandelow, B.
 1996
 6 S4 p. S4-152-
1 p.
 artikel
235 Panic disorder: Do we know the best way to treat it? Anderson, I.M.
 1996
 6 S4 p. S4-47-S4-48
NaN p.
 artikel
236 Patterns of mood improvement with mirtazapine Kremer, C.M.E.
 1996
 6 S4 p. S4-61-
1 p.
 artikel
237 Peculiarifies of psychopharmacotherapy for prolonged depressive-delusional states with resistance phenomena Emelyanova, I.N.
 1996
 6 S4 p. S4-128-
1 p.
 artikel
238 Peduncular hallucinosis: SSRI efficacy brings new arguments for an old theory Gilles, C.
 1996
 6 S4 p. S4-94-S4-95
NaN p.
 artikel
239 Personality disorders are disorders of the personality López-Ibor Jr., J.J.
 1996
 6 S4 p. S4-1-S4-2
NaN p.
 artikel
240 PET imaging of benzodiazepine receptors and their relationship to anxiety disorders Nutt, D.J.
 1996
 6 S4 p. S4-19-
1 p.
 artikel
241 PET studies on the dopamine system in vivo Farde, L.
 1996
 6 S4 p. S4-8-
1 p.
 artikel
242 Pharmacoethological investigation GABA-ergic regulation of aggression and depression: Animal models Belozertseva, I.V.
 1996
 6 S4 p. S4-77-S4-78
NaN p.
 artikel
243 Pharmacokinetic-pharmacodynamic modelling of the interaction between phenytoin and sodium valproate Della Paschoa, O.E.
 1996
 6 S4 p. S4-160-S4-161
NaN p.
 artikel
244 Pharmacokinetics and relevance for choice Delbressine, L.P.C.
 1996
 6 S4 p. S4-64-
1 p.
 artikel
245 Pharmacological discrimination of native and recombinant rat and human N-methyl-D-aspartate receptors Priestley, T.
 1996
 6 S4 p. S4-49-S4-50
NaN p.
 artikel
246 Pharmacological treatment of social phobia: A controlled study with alprozolam and buspirone Krylov, V.I.
 1996
 6 S4 p. S4-144-
1 p.
 artikel
247 Pharmacology and the relevance for choice Preskorn, S.H.
 1996
 6 S4 p. S4-63-
1 p.
 artikel
248 Pharmacology of benzodiazepine receptor ligands with different intrinsic efficacy Stephens, D.N.
 1996
 6 S4 p. S4-18-S4-19
NaN p.
 artikel
249 Pharmacology of the presynaptic terminal: Modifications induced by antidepressant treatment in the phosphorylation of synaptotagmin and its functional properties Popoli, M.
 1996
 6 S4 p. S4-81-S4-82
NaN p.
 artikel
250 Pharmaco-psychological effects of S(+) DN-3227 enantiomer and DN-2327 racemate Dietrich, B.
 1996
 6 S4 p. S4-150-
1 p.
 artikel
251 Pharmacotherapy and brief dynamic psychotherapy of panic disorder Dahl, A.A.
 1996
 6 S4 p. S4-143-
1 p.
 artikel
252 Phencyclidine (PCP) alters excitability in CA1 hippocampal neurons by inhibiting local circuit inhibition and increasing transmembraneous calcium influx Grunze, H.
 1996
 6 S4 p. S4-101-
1 p.
 artikel
253 Pindolol augments the antidepressant efficacy of fluoxetine. Results of a double-blind, controlled trial Pérez, V.
 1996
 6 S4 p. S4-88-S4-89
NaN p.
 artikel
254 Plasma arginine vasopressin and motor activity in patients with major depression and in healthy controls van Londen, L.
 1996
 6 S4 p. S4-86-
1 p.
 artikel
255 Platelet serotonin, 3H-paroxetine binding and recurrent suicide attempts: A one-year follow up study Verkes, R.J.
 1996
 6 S4 p. S4-67-
1 p.
 artikel
256 Positron emission tomography in schizophrenic patients treated with sertindole and haloperidol Buchsbaum, M.S.
 1996
 6 S4 p. S4-109-
1 p.
 artikel
257 Possible cross-tolerance between haloperidol and clozapine towards Fos-protein induction in some rat brain regions Sebens, Jantiena B.
 1996
 6 S4 p. S4-28-S4-29
NaN p.
 artikel
258 Potentiation of antidepressants with lithium or carbamazepine Suwalska, A.
 1996
 6 S4 p. S4-87-
1 p.
 artikel
259 Pramipexole as an adjunct to haloperidol in schizophrenia Barnas, C.
 1996
 6 S4 p. S4-114-
1 p.
 artikel
260 Preliminary findings on the role of fluvoxamine in the treatment of alcoholism Vrasti, Vadu
 1996
 6 S4 p. S4-138-S4-139
NaN p.
 artikel
261 Prevalence of refractory depression and therapeutic strategies in an italian out-patient mental health department Jansen, A.
 1996
 6 S4 p. S4-120-
1 p.
 artikel
262 Prodromes of schizophrenia Maurer, K.
 1996
 6 S4 p. S4-59-S4-60
NaN p.
 artikel
263 Prolactin and TSH responses to TRH and to ECT in pre- and post-menopausal women with major depression Lykouras, E.
 1996
 6 S4 p. S4-69-
1 p.
 artikel
264 Prolyl-leucyl-glycinamide, thyrotropin releasing hormone and β-endorphin-(10–16), like antidepressants, inhibit the effects of melatonin on rat behaviour Wolterink, G.
 1996
 6 S4 p. S4-86-S4-87
NaN p.
 artikel
265 Psychiatric and psychosocial assessment of deliberate self-mutulation in: A controlled study Çetin, M.
 1996
 6 S4 p. S4-158-S4-159
NaN p.
 artikel
266 Quantitative video-analysis of gait in depressed inpatients Hergueta, T.
 1996
 6 S4 p. S4-91-
1 p.
 artikel
267 Rapid onset of antidepressant action in an animal model of depression Papp, M.
 1996
 6 S4 p. S4-22-
1 p.
 artikel
268 Rat tardive dyskinesia is mediated by PI linked D-1 dopamine receptor subtype Rosengarten, H.
 1996
 6 S4 p. S4-112-S4-113
NaN p.
 artikel
269 Receptors for ATP: New structures and new therapeutic targets Barnard, E.A.
 1996
 6 S4 p. S4-2-
1 p.
 artikel
270 Reduced Gs protein function and Gαs levels in leukocytes of patients with Parkinson's disease Barki-Harrington, L.
 1996
 6 S4 p. S4-100-S4-101
NaN p.
 artikel
271 Reduced 5-HT in CSF: Trait or state marker for suicidality? Becker, U.
 1996
 6 S4 p. S4-79-S4-80
NaN p.
 artikel
272 Reduction of hospital days in sertindole treated patients-one year findings Braus, A.
 1996
 6 S4 p. S4-109-S4-110
NaN p.
 artikel
273 Reduction of the positive symptoms of schizophrenia by ‘Seroquel’ (ICI 204,636): Results from phase II and III clinical trials Hong, W.W.
 1996
 6 S4 p. S4-125-
1 p.
 artikel
274 Regulation of AP-1 transcription complex in the CNS by antipsychotics Rogue, P.
 1996
 6 S4 p. S4-114-
1 p.
 artikel
275 Regulation of AP-1 transcription complex in the CNS by antipsychotics Rogue, P.
 1996
 6 S4 p. S4-115-
1 p.
 artikel
276 Relapse prevention with neuroleptics in schizophrenia: The role of their bioavailability and pharmacodynamic profile Altamura, A.C.
 1996
 6 S4 p. S4-32-S4-33
NaN p.
 artikel
277 Repeated flesinoxan administration in rats: Dissociation of hormonal and behavioural effects Groenink, L.
 1996
 6 S4 p. S4-146-
1 p.
 artikel
278 Response to risperidone in schizophrenic in-patients refractory to antipsychotics Bussé, D.
 1996
 6 S4 p. S4-123-
1 p.
 artikel
279 Responsiveness of rabbit detrusor, urethra, and trigone strips to imipramine and trazodone Tita, B.
 1996
 6 S4 p. S4-82-S4-83
NaN p.
 artikel
280 Responsiveness of rabbit prostate strips to imipramine and trazodone Tita, B.
 1996
 6 S4 p. S4-83-
1 p.
 artikel
281 Results of cognitive-behavioral therapy supported by piracetam and computerized cognitive skills (re)training in alcoholics Schett, P.
 1996
 6 S4 p. S4-136-
1 p.
 artikel
282 RIMAs in social phobia Buller, R.
 1996
 6 S4 p. S4-39-
1 p.
 artikel
283 Risperidone in the treatment of Gilles de la Tourette Syndrome Stamenkovic, M.
 1996
 6 S4 p. S4-163-
1 p.
 artikel
284 Risperidone in the treatment of psychosis and concomitant buccolinguo-masticatory dyskinesis Koponen, H.J.
 1996
 6 S4 p. S4-117-S4-118
NaN p.
 artikel
285 Risperidone in the treatment of rapid cycling bipolar disorder Vieta, E.
 1996
 6 S4 p. S4-64-S4-65
NaN p.
 artikel
286 Risperidone is well tolerated by organic brain syndromes Pourcher, E.
 1996
 6 S4 p. S4-99-
1 p.
 artikel
287 Risperidone treatment of schizophrenia: Clinical experience Spisla, C.
 1996
 6 S4 p. S4-104-
1 p.
 artikel
288 Role of inflammation, Apo E, and antichymotrypsin in Alzheimer's disease Potter, Huntington
 1996
 6 S4 p. S4-26-
1 p.
 artikel
289 Role of noradrenergic, dopaminergic, serotonergic and opioidergic systems on the effect of neonatal handling in learned helplessness Tejedor-Real, P.
 1996
 6 S4 p. S4-157-S4-158
NaN p.
 artikel
290 Safety of mirtazapine in overdose Zivkov, M.
 1996
 6 S4 p. S4-62-
1 p.
 artikel
291 Safety profile of flesinoxan; results form a meta-analysis of studies in patients with major depressive disorder or generalised anxiety disorder de Voogd, J.M.
 1996
 6 S4 p. S4-143-S4-144
NaN p.
 artikel
292 Salivary cortisol response to psychological stress in healthy adults and children: Comparison of two different stimuli Jansan, L.M.C.
 1996
 6 S4 p. S4-164-
1 p.
 artikel
293 Selective serotonin reuptake inhibitors: Adverse drug reactions registered by SANZ-Swiss spontaneous reporting system Spisla, C.
 1996
 6 S4 p. S4-71-
1 p.
 artikel
294 Selective versus non-selective neuroleptics: Advantages and disadvantages Ackenheil, M.
 1996
 6 S4 p. S4-22-
1 p.
 artikel
295 ‘Seroquel’ (ICI 204,636)-Efficacy in treating the negative symptoms of schizophrenia Hurst, B.C.
 1996
 6 S4 p. S4-124-
1 p.
 artikel
296 Serotonergic mechanisms in the pathophysiology of seasonal affective disorder Neumeister, A.
 1996
 6 S4 p. S4-66-S4-67
NaN p.
 artikel
297 Serotonin depletion affects both motor and anti-conflict effects of competitive and noncompetitive NMDA receptor antagonists Jessa, M.
 1996
 6 S4 p. S4-154-
1 p.
 artikel
298 Serotoninergic activity in eating disorders subtypes Ramacciotti, C.E.
 1996
 6 S4 p. S4-167-
1 p.
 artikel
299 Serotonin-related strategies for the treatment of schizophrenia Meltzer, H.Y.
 1996
 6 S4 p. S4-20-S4-21
NaN p.
 artikel
300 Social defeat in rats as model for depression Koolhaas, J.M.
 1996
 6 S4 p. S4-35-
1 p.
 artikel
301 Social functioning and psychopathology of people in long-term psychiatric day care. Influence of new and classical neuroleptics on patient's outcome Nicolaou, S.
 1996
 6 S4 p. S4-116-
1 p.
 artikel
302 Social phobia: Treatment usage in general health care Weiller, E.
 1996
 6 S4 p. S4-37-
1 p.
 artikel
303 Stimulation of serotonin (5-HT)1A autoreceptors enhances dopamine (DA) and noradrenaline (NAD) release in rat frontal cortex: influence of S 15535, WAY 100,635 and 8-OH-DPAT Lejeune, F.
 1996
 6 S4 p. S4-121-S4-122
NaN p.
 artikel
304 Stimulus properties of mirtazapine resemble those of a 5-HT1A receptor agonist Berendsen, H.H.G.
 1996
 6 S4 p. S4-82-
1 p.
 artikel
305 Stress and depression: A hypothesis on their biological interface van Praag, H.M.
 1996
 6 S4 p. S4-34-S4-35
NaN p.
 artikel
306 Studies in nonhuman primates provide insights into the dysregulation of emotional responses and psychopathology Kalin, N.H.
 1996
 6 S4 p. S4-52-
1 p.
 artikel
307 Studies of cerebral blood flow with SPET and PET — Promises and pitfalls McGuire, P.K.
 1996
 6 S4 p. S4-8-S4-9
NaN p.
 artikel
308 Study of maternal influenza during pregnancy as a risk factor in schizophrenia Rouillon, F.
 1996
 6 S4 p. S4-110-S4-111
NaN p.
 artikel
309 Survival analysis of patients with one vs. multiple treatment attempts in a naltrexone program Ochoa, E.
 1996
 6 S4 p. S4-137-
1 p.
 artikel
310 Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic (‘Seroquel’ ’ ICI 204,636) Hellewell, J.S.E.
 1996
 6 S4 p. S4-123-
1 p.
 artikel
311 Sympatho-adrenomedullary activity during mental stress and orthostatic challenge: Effects of alprozolam and lorazepam Tulen, J.H.M.
 1996
 6 S4 p. S4-142-
1 p.
 artikel
312 Synergistic increases of noradrenaline and 5-HT neurotransmission induced by milnacipran with pindolo Moret, C.
 1996
 6 S4 p. S4-68-
1 p.
 artikel
313 The amyloid hypothesis in Alzheimer's disease and its implication for therapy: A review of evidence Beyreuther, K.
 1996
 6 S4 p. S4-24-S4-25
NaN p.
 artikel
314 The analgetic activity of the new analog of ACTH (4–) fragment in patients with migraine attack Dubinin, V.A.
 1996
 6 S4 p. S4-156-S4-157
NaN p.
 artikel
315 The antidepressant effect and tolerability of moclobemide — elderly versus younger patients Stanković, Ž.
 1996
 6 S4 p. S4-88-
1 p.
 artikel
316 The atypical profile of ‘Seroquel’ (ICI 204,636) is supported by its lack of inductionof extrapyramidal symptoms Hong, W.W.
 1996
 6 S4 p. S4-125-
1 p.
 artikel
317 The atypical profile of ‘Seroquel’ (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients Hong, W.W.
 1996
 6 S4 p. S4-124-S4-125
NaN p.
 artikel
318 The behavioral and neural biology of “social stress” Miczek, K.A.
 1996
 6 S4 p. S4-36-S4-37
NaN p.
 artikel
319 The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects Puechler, K.
 1996
 6 S4 p. S4-65-S4-66
NaN p.
 artikel
320 The course of primary and secondary negative symptoms in a placebo-and comparator-controlled trial of the typical antipsychotic olanzapine Tollefson, G.D.
 1996
 6 S4 p. S4-14-
1 p.
 artikel
321 The development of brain and behavior Insel, Thomas R.
 1996
 6 S4 p. S4-51-
1 p.
 artikel
322 The development of home-seeking behavior in rat pups Sigling, Hein O.
 1996
 6 S4 p. S4-154-S4-155
NaN p.
 artikel
323 The dopamine receptors and schizophrenia therapy Civelli, Olivier
 1996
 6 S4 p. S4-19-S4-20
NaN p.
 artikel
324 The effect of ACPC, a partial agonist of glycine receptors, on motivational aspects of morphine dependence Papp, M.
 1996
 6 S4 p. S4-132-
1 p.
 artikel
325 The effect of antidepressants on platelet serotonin level and serotonin uptake in rats genetically selected for these traits Čičin-Šain, L.
 1996
 6 S4 p. S4-76-S4-77
NaN p.
 artikel
326 The effect of antimanic drugs on the hypermotility response to intracerebroventricular administration of ouabain in the rat Piper, D.C.
 1996
 6 S4 p. S4-70-S4-71
NaN p.
 artikel
327 The effect of chronic naltrexone treatment on hyperactive behaviour in children with autism Willemsen-Swinkels, S.H.N.
 1996
 6 S4 p. S4-166-
1 p.
 artikel
328 The effect of ethnic belonging of drug addicts on the structure and the treatment period of the abstinent syndrome for some forms of drug addiction Krivogornitsina, H.A.
 1996
 6 S4 p. S4-139-
1 p.
 artikel
329 The effect of neuroleptic drugs on olfactory sensitivity in schizophrenia Sirota, Pinkhas
 1996
 6 S4 p. S4-114-
1 p.
 artikel
330 The effect of the neuroactive steroid α-THDOC, on staircase test behavior in mice Weizman, R.
 1996
 6 S4 p. S4-150-
1 p.
 artikel
331 The effects of a new RIMA antidepressant RS-8359 on cardiovascular function Puechler, K.
 1996
 6 S4 p. S4-66-
1 p.
 artikel
332 The effects of benzodiazepines — hypnotics on performance and recent memory during the therapy of isomnia in schizophrenic patients Jasovic-Gasic, M.
 1996
 6 S4 p. S4-113-S4-114
NaN p.
 artikel
333 The effects of delta sleep inducing peptide on burying behavior in rats with active and passive behavioral strategies Strekalova, T.V.
 1996
 6 S4 p. S4-158-
1 p.
 artikel
334 The effects of meta-chlorophenylpiperazine at cerebral blood flow and behavior in Obsessive Compulsive Disorder (OCD). Is the cerebellum involved in OCD? Ho Pian, K.L.
 1996
 6 S4 p. S4-151-
1 p.
 artikel
335 The effects of neonatal bilateral ventral hippocampal lesions on behavior in the rat Daenen, E.W.P.M.
 1996
 6 S4 p. S4-127-
1 p.
 artikel
336 The effects of neuroleptics in rats with neonatal hippocampal damage; A search for more effective treatment of schizophrenia Lipska, B.K.
 1996
 6 S4 p. S4-44-S4-45
NaN p.
 artikel
337 The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients Baker, R.W.
 1996
 6 S4 p. S4-109-
1 p.
 artikel
338 The evaluation of fluvoxamine in the treatment of social phobia DeVane, C.L.
 1996
 6 S4 p. S4-153-
1 p.
 artikel
339 The future of CCK agonists and antagonists in panic disorder and anxiety Bourin, M.
 1996
 6 S4 p. S4-48-
1 p.
 artikel
340 The involvement of voltage-dependent Ca2+ channel in effects of acutely and chronically administered LSD on biogenic amine metabolism in various areas of rat brain Antkiewicz-Michaluk, Lucyna
 1996
 6 S4 p. S4-131-
1 p.
 artikel
341 The need for treatment of social phobia Costa e Silva, J.A.
 1996
 6 S4 p. S4-39-
1 p.
 artikel
342 The NMDA receptor and the olfactory bulbectomised rat model of depression Redmond, A.M.
 1996
 6 S4 p. S4-87-S4-88
NaN p.
 artikel
343 The opinion about mental illness, with respect to general psychopathology and personality characteristics, in a sample of subjects of a small greek island Trikkas, G.
 1996
 6 S4 p. S4-165-
1 p.
 artikel
344 The patient under neuroteptic treatment: Study of prescription practice in psychiatry in France Lachaux, B.
 1996
 6 S4 p. S4-110-
1 p.
 artikel
345 The pharmacology of native NMDA receptor subtypes Carter, C.
 1996
 6 S4 p. S4-50-S4-51
NaN p.
 artikel
346 The place of cognitive therapy in the treatment of obsessive compulsive disorder van Oppen, P.
 1996
 6 S4 p. S4-16-
1 p.
 artikel
347 The preclinical profile of an original pyridobenzoxazepine, JL 13 Lié, J.-F.
 1996
 6 S4 p. S4-112-
1 p.
 artikel
348 The presynaptic release apparatus: A main site in the mechanism of action of psychotropic drugs Popoli, M.
 1996
 6 S4 p. S4-81-
1 p.
 artikel
349 Therapeutical approaches to sexual disadaptation Kibrik, N.D.
 1996
 6 S4 p. S4-167-
1 p.
 artikel
350 Therapeutic monitoring of amitriptyline, fluvoxamine and lithium in depressed patients on combined therapy Miljković, B.
 1996
 6 S4 p. S4-73-S4-74
NaN p.
 artikel
351 The relevance of prolonged aversive stimulation stress model for the research of anxious and depression Sukhotina, I.A.
 1996
 6 S4 p. S4-139-
1 p.
 artikel
352 The role of nitric oxide in chemically and electrically induced convulsions in mice Przegaliński, E.
 1996
 6 S4 p. S4-160-
1 p.
 artikel
353 The safety and tolerability profile of a new RIMA antidepressant, RS-8359 in healthy subjects and depressed patients Puechler, K.
 1996
 6 S4 p. S4-66-
1 p.
 artikel
354 The safety of ‘Seroquel’ (ICI 204,636) in the treatment of elderly subjects with psychotic disorders Hong, W.W.
 1996
 6 S4 p. S4-126-
1 p.
 artikel
355 The safety profile of amisulpride, an “atypical” antipsychotic Favennec, C.
 1996
 6 S4 p. S4-111-
1 p.
 artikel
356 The safety profile of fluvoxamine in elderly patients Wagner, W.
 1996
 6 S4 p. S4-65-
1 p.
 artikel
357 The treatment of dysthymic patients: Fluvoxamine versus amitriptyline Amore, Mario
 1996
 6 S4 p. S4-85-
1 p.
 artikel
358 The treatment of the schizophrenic patient: How far have we come in meeting the challenge Kane, J.M.
 1996
 6 S4 p. S4-12-S4-13
NaN p.
 artikel
359 The Vienna outpatient-clinic for therapy-resistant depression Lenz, G.
 1996
 6 S4 p. S4-69-S4-70
NaN p.
 artikel
360 Thrombocyte monoamine oxidase molecular activity in demented and parkinsonian patients Bongioanni, P.
 1996
 6 S4 p. S4-97-
1 p.
 artikel
361 Thrombocyte phenolsulphotransferase and monoamine oxidase activity, and benzodiazepine binding in patients with dementia of Alzheimer type Bongioanni, P.
 1996
 6 S4 p. S4-97-S4-98
NaN p.
 artikel
362 Thyroid function and seizure time during ECT Papakostas, Y.
 1996
 6 S4 p. S4-84-
1 p.
 artikel
363 Time-blind assessment of antidepressant efficacy in depressed patients Corruble, E.
 1996
 6 S4 p. S4-79-
1 p.
 artikel
364 Time course of inositol treatment of panic disorder Benjamin, J.
 1996
 6 S4 p. S4-48-S4-49
NaN p.
 artikel
365 Tolerance and therapeutic response of paroxetine in the depressed elderly De la Serna, I.
 1996
 6 S4 p. S4-72-
1 p.
 artikel
366 Toxicity of antidepressant drugs: A comparative in vitro study Lisch, S.
 1996
 6 S4 p. S4-75-
1 p.
 artikel
367 Trazodone versus clonidine in rapid detoxification from opiates Conte, G.L.
 1996
 6 S4 p. S4-134-S4-135
NaN p.
 artikel
368 Treating poor prognosis schizophrenia Chinchilla Moreno, A.
 1996
 6 S4 p. S4-104-S4-105
NaN p.
 artikel
369 Treatment costs of schizophrenic patients Thys, E.
 1996
 6 S4 p. S4-121-
1 p.
 artikel
370 Treatment maintenance time in panic disorder with or without agoraphobia Corominas, A.
 1996
 6 S4 p. S4-140-
1 p.
 artikel
371 Treatment of inhalation toxicomania with phenothiazine piperazine derivatives (PPD) Mikhailov, M.A.
 1996
 6 S4 p. S4-137-
1 p.
 artikel
372 Treatment of sleep disturbance and pain syndrome in fibromyalgia patients with the 5-HT2-receptor antagonist ketanserine Hemmeter, U.
 1996
 6 S4 p. S4-69-
1 p.
 artikel
373 Treatment of social phobia with SSRIs Greist, J.H.
 1996
 6 S4 p. S4-38-S4-39
NaN p.
 artikel
374 Treatment options in refractory bipolar disorder, methodological problems and clinical opportunities Nolen, Willem A.
 1996
 6 S4 p. S4-31-
1 p.
 artikel
375 Treatment outcome in poor metabolizers versus extensive metabolizers in a population of psychotic patients in Denmark and Norway Bjarking, L.
 1996
 6 S4 p. S4-153-
1 p.
 artikel
376 Tryptophan depletion and neurohormonal regulation in remitted patients with seasonal affective disorder Hesselmann, B.
 1996
 6 S4 p. S4-78-
1 p.
 artikel
377 Two long-term neuroleptic resistant patients treated by ‘Seroquel’ (ICI 204,636) an atypical neuroleptic Avnon, M.
 1996
 6 S4 p. S4-124-
1 p.
 artikel
378 Urinary excretion of cortisol, norepinephrine, epinephrine, testosterone, and melatonin in panic disorder Bandelow, B.
 1996
 6 S4 p. S4-152-
1 p.
 artikel
379 Use of dopaminergic agonist in treatment of chronic depressive patients resistant to tricyclic antidepressants Tsucarzi, E.
 1996
 6 S4 p. S4-90-S4-91
NaN p.
 artikel
380 Use of psychotropic medication before and after psychotherapeutic inpatient treatment Laux, G.
 1996
 6 S4 p. S4-161-S4-162
NaN p.
 artikel
381 Utilization of laser therapy in the complex treatment of Tourette's syndrome in children Janumova, G.M.
 1996
 6 S4 p. S4-168-
1 p.
 artikel
382 Vitamin E inhibits cellular accumulation of desipramine and prevents antidepressant induced β-adrenoceptor down-regulation in vitro and in vivo Kientsch, U.
 1996
 6 S4 p. S4-91-
1 p.
 artikel
                             382 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland